Immunology
| 7 min read
CAR T has transformed treatment for some blood cancers, but manufacturing and healthcare system constraints still prevent many eligible patients from receiving it.
| 3 min read
Researchers at Erasmus MC and Apeximmune independently identified PLA2G2D as a potential new target for restoring antitumor T cell responses.
| 5 min read
The science behind personalized mRNA cancer vaccines is working. Building a different drug for every patient, at scale, is the real fight.
| 6 min read
Bacteria have been linked to cancer treatment for more than a century. Now researchers are trying to turn them into actual therapies.
| 3 min read
Beyond mRNA vaccines, siRNA and antisense therapies are advancing as chemistry, AI, and manufacturing finally keep pace with clinical ambition.
| 4 min read
The Nurix and Roche partnership on bexobrutideg is the latest sign that targeted protein degradation is moving well beyond oncology.
| 3 min read
The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant.
| 4 min read
Results from Johns Hopkins show a synthetic peptide vaccine was safe and activated mutant-KRAS-specific T cells in 90 percent of participants, offering an early signal that cancer interception may be possible before disease develops.
| 3 min read
Researchers find that infant airway tissue actively shapes the immune response to RSV, suggesting future therapies should target both the virus and inflammation.
| 5 min read
Therapeutic cancer vaccines are being reengineered to deliver stronger immune activation and longer-lasting protection against disease recurrence.
| 3 min read
Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.
| 4 min read
Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need.
